Tag: U.K.
-
Infographic – Immigrants Boost U.S. Nobel Prizes
The U.S. dominates Nobel prizes in the sciences — physics, chemistry, medicine, and economics — and immigrants to the U.S. contribute a large chunk of those awards.
-
Skeletal Stem Cells Enhanced for Bone Repair
Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulated skull defects.
-
Mental Health Drug Company Raises $127.5M in IPO
A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer.
-
Point-of-Care Covid-19 Diagnostic Shows High Accuracy
A test for SARS-CoV-2 viruses in humans is shown in field tests to return diagnostic results in 90 minutes with accuracy comparable to the gold-standard RT-PCR test.
-
Sanofi, GSK Begin U.S. Covid-19 Vaccine Trial
Global drug makers Sanofi and GlaxoSmithKline are starting a clinical trial testing a vaccine to prevent Covid-19 infections among healthy adults in the U.S.
-
Late-Stage Covid-19 Vaccine Trial Underway in U.S.
Global drug maker AstraZeneca is starting its late-stage Covid-19 vaccine clinical trial in the U.S., with a vow not to cut corners in its processes.
-
Engineered Mosquitoes Approved for Disease Control
In an apparent end to a long-running dispute, authorities in the Florida Keys approved a field trial of engineered mosquitoes to control tropical diseases.
-
Synthetic Protein Maker Raises $91.3M in Venture Funds
A company creating animal-free designer proteins for skin care products is raising more than $91 million in its second venture funding round.
-
Trial Testing Point-of-Care Covid-19 Diagnostic
A clinical trial in the U.K. is assessing a testing device to detect Covid-19 viruses in nasal swab samples that returns results in an hour.
-
Oxford Covid-19 Vaccine Trial Invokes Immune Responses
Results from a clinical trial testing a Covid-19 vaccine show the vaccine invokes two types of immune responses without serious adverse effects.